2月27日周四,百济神州(ONC)在盘前交易中大涨5.79%,股价上涨引发了市场的广泛关注。从最新财报来看,该公司业绩表现优异,核心产品销售额快速攀升,这些有力因素共同推动了股价的大幅上行。
百济神州自主研发的核心产品之一百悦泽(泽布替尼胶囊)取得了令人瞩目的销售成绩。2024年度,该产品全球销售额达到188.59亿元人民币,同比大幅增长106.4%,其中美国市场销售额138.9亿元,同比增长107.5%;欧洲市场销售额25.64亿元,同比增长195.4%。百悦泽已获批多个适应症,在治疗血液肿瘤领域具有领先优势。
另一核心产品百泽安(替雷利珠单抗)在2024年同样实现了显著销售增长,全年销售额达44.67亿元,同比增长17.4%,目前已在中国市场获批多项适应症纳入医保目录。此外公司在多个新产品的研发进展顺利,有望进一步提升竞争力和盈利能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.